{"id":70705,"date":"2026-05-12T09:29:41","date_gmt":"2026-05-12T09:29:41","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70705"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"oxytocin-acetate","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/oxytocin-acetate\/","title":{"rendered":"Ac\u00e9tate d'ocytocine"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'ac\u00e9tate d'ocytocine ?<\/h3>\n<p style=\"margin: 0;\"><strong>Ac\u00e9tate d'ocytocine<\/strong> is the acetate-salt form of oxytocin, a 9-amino-acid cyclic neuropeptide with a single disulfide bridge between Cys1 and Cys6. It is one of the oldest and most extensively studied neuropeptides in published studies, acting as both a hypothalamic hormone (uterine contraction, milk ejection) and a central neuromodulator of social bonding, trust, and affiliative behaviour. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">50-56-6 (base libre d'ocytocine) ; fourni sous forme de sel d'ac\u00e9tate<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>43<\/sub>H<sub>66<\/sub>N<sub>12<\/sub>O<sub>12<\/sub>S<sub>2<\/sub> (base libre ; le sel d'ac\u00e9tate ajoute un contre-ion CH<sub>3<\/sub>COOH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1007.19 Da (base libre)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH<sub>2<\/sub> (CYIQNCPLG-NH<sub>2<\/sub>, 9 acides amin\u00e9s ; pont disulfure intramol\u00e9culaire Cys<sup>1<\/sup>\u2013Cys<sup>6<\/sup> formant un anneau macrocyclique \u00e0 6 r\u00e9sidus avec une queue C-terminale \u00e0 3 r\u00e9sidus ; C-terminal amid\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sel d'ac\u00e9tate lyophilis\u00e9 (poudre blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bacteriostatic water (recommended) or sterile water for shorter use windows. Compatible with intranasal vehicle formulations.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'oxytocine ac\u00e9tate ?<\/h2>\n<p><strong>Ac\u00e9tate d'ocytocine<\/strong> is the acetate-salt form of oxytocin, a 9-amino-acid cyclic neuropeptide first isolated by Sir Henry Dale in 1906 and chemically synthesised by Vincent du Vigneaud in 1953 \u2014 the first peptide hormone ever produced by total synthesis, work that earned du Vigneaud the 1955 Nobel Prize in Chemistry. The acetate counterion is used in pharmaceutical-grade lyophilization because it improves long-term peptide stability and water solubility relative to free-base oxytocin without altering pharmacology \u2014 the acetate dissociates rapidly in physiological solution. The well-characterised sequence is CYIQNCPLG-NH<sub>2<\/sub> avec un pont disulfure intramol\u00e9culaire entre Cys1 et Cys6 qui cr\u00e9e un cycle macrocyclique \u00e0 6 r\u00e9sidus et une queue C-terminale \u00e0 3 r\u00e9sidus. La masse mol\u00e9culaire est de 1007,19 Da (forme libre) ; formule empirique C<sub>43<\/sub>H<sub>66<\/sub>N<sub>12<\/sub>O<sub>12<\/sub>S<sub>2<\/sub>. Oxytocin is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For related small-peptide CNS studies, see our <a href=\"https:\/\/medsbase.com\/fr\/selank\/\">Selank<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141<\/a> pages produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 R\u00f4les endocriniens p\u00e9riph\u00e9riques et neuromodulateurs centraux<\/h2>\n<p>What makes oxytocin unusual among peptides is its <strong>double identit\u00e9<\/strong> en tant qu'hormone endocrine p\u00e9riph\u00e9rique et neuromodulateur central. La m\u00eame mol\u00e9cule, lib\u00e9r\u00e9e \u00e0 partir de diff\u00e9rents compartiments anatomiques, produit des effets physiologiques fondamentalement diff\u00e9rents :<\/p>\n<ul>\n<li><strong>Lib\u00e9ration endocrine p\u00e9riph\u00e9rique \u2014 effets ut\u00e9rins et mammaires<\/strong> \u2014 L'ocytocine est synth\u00e9tis\u00e9e dans les neurones magnocellulaires des noyaux supraoptique et paraventriculaire de l'hypothalamus et lib\u00e9r\u00e9e dans la circulation syst\u00e9mique par la posthypophyse. L'ocytocine p\u00e9riph\u00e9rique se lie aux r\u00e9cepteurs OXTR sur le muscle lisse ut\u00e9rin (stimulant les contractions pendant le travail) et sur les cellules myo\u00e9pith\u00e9liales des alv\u00e9oles mammaires (entra\u00eenant le r\u00e9flexe d'\u00e9jection du lait). La demi-vie p\u00e9riph\u00e9rique est courte (~3\u20135 minutes IV) en raison d'un m\u00e9tabolisme rapide par l'ocytocinase et d'autres peptidases.<\/li>\n<li><strong>Lib\u00e9ration centrale \u2014 comportement social, affiliatif et de tamponnement du stress<\/strong> \u2014 A separate population of parvocellular oxytocin neurons projects axonally into brain regions including the amygdala, nucleus accumbens, ventral tegmental area, and prefrontal cortex. Central oxytocin release does not enter systemic circulation and is not measured by plasma assays. In published studies it modulates pair-bonding, in-group affiliation, trust, fear extinction, and stress reactivity. The prairie-vole pair-bonding literature is the canonical mechanistic dataset for central oxytocin signalling.<\/li>\n<li><strong>Pharmacologie des r\u00e9cepteurs et transduction du signal<\/strong> \u2014 L'ocytocine agit sur un seul r\u00e9cepteur coupl\u00e9 aux prot\u00e9ines G (OXTR), qui se couple principalement \u00e0 G\u03b1<sub>q\/11<\/sub> pour activer la phospholipase C, l'IP<sub>3<\/sub>, et la lib\u00e9ration de calcium intracellulaire dans le muscle lisse. Dans le SNC, la signalisation OXTR est plus complexe et inclut le couplage G\u03b1<sub>i\/o<\/sub> coupling, modulation of GABAergic interneurons, and crosstalk with the closely-related vasopressin V1a receptor. Selective OXTR agonists and antagonists are heavily used in current studies to dissect oxytocin vs vasopressin contributions to behaviour.<\/li>\n<\/ul>\n<p>The intranasal administration route is one of the most-cited studies delivery methods because it produces measurable CNS effects on social behaviour without raising peripheral plasma oxytocin to physiologically meaningful levels. The exact mechanism by which intranasal oxytocin reaches CNS compartments \u2014 whether through olfactory and trigeminal nerve transport, cribriform plate diffusion, or a peripheral feedback signal \u2014 remains an active studies question. The behavioural effects are reproducible enough that intranasal administration has become the standard route in human and rodent oxytocin behavioural support. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Oxytocin Acetate is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Comportement social et formation de liens de couple<\/strong> \u2014 tests de pr\u00e9f\u00e9rence de partenaire chez le campagnol des prairies, formation de la pr\u00e9f\u00e9rence de partenaire chez les campagnols monogames vs polygames, paradigmes de reconnaissance sociale chez les rongeurs (Insel &amp; Hulihan, Behav Neurosci 1995 ; Young &amp; Wang, Nat Neurosci 2004)<\/li>\n<li><strong>Autism spectrum and social-cognition studies<\/strong> \u2014 preclinical models of social-deficit phenotypes, OXTR variant cohort studies, intranasal oxytocin behavioural endpoints; one of the most active areas of contemporary oxytocin clinical studies<\/li>\n<li><strong>Trust and cooperation behavioural support<\/strong> \u2014 paradigmes \u00e9conomiques du jeu de confiance, prise de d\u00e9cision coop\u00e9rative sous incertitude ; modulation des biais intra-groupe vs inter-groupe<\/li>\n<li><strong>Stress, anxi\u00e9t\u00e9 et extinction de la peur<\/strong> \u2014 amygdala-dependent fear conditioning, stress-induced HPA-axis activation, cortisol response modulation in published studies<\/li>\n<li><strong>Comportement maternel et soins parentaux<\/strong> \u2014 postpartum maternal-behaviour induction in rodents, paternal-care studies in monogamous vole species, alloparental behaviour<\/li>\n<li><strong>Reproductive physiology studies<\/strong> \u2014 uterine contractility assays, mammary myoepithelial-cell studies, labour and parturition mechanism studies<\/li>\n<li><strong>Cicatrisation et r\u00e9g\u00e9n\u00e9ration tissulaire<\/strong> \u2014 OXTR expression on dermal fibroblasts and keratinocytes; emerging studies on local oxytocin signalling in cutaneous wound repair<\/li>\n<li><strong>Comparative neuropeptide studies<\/strong> \u2014 comparaison avec la vasopressine (neuropeptide cyclique \u00e0 9 acides amin\u00e9s \u00e9troitement apparent\u00e9 avec une diff\u00e9rence d'un acide amin\u00e9) et avec d'autres petits peptides actifs dans le SNC tels que <a href=\"https:\/\/medsbase.com\/fr\/selank\/\">Selank<\/a>.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place de l'ocytocine dans le paysage des neuromodulateurs \u00e0 petits peptides, voir <a href=\"https:\/\/medsbase.com\/fr\/selank\/\">Selank<\/a> (heptapeptide anxiolytique), <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141<\/a> (agoniste des m\u00e9lanocortines actif sur le SNC), et <a href=\"https:\/\/medsbase.com\/fr\/semax\/\">Semax<\/a> (heptapeptide nootropique). Parcourez l'int\u00e9gralit\u00e9 de <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Oxytocin Acetate in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, intranasal-vehicle formulation, behavioural-test protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lowest per-mg cost, multi-cohort behavioural studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Because oxytocin&#8217;s dose range is in the low-microgram-per-administration regime, a single 5\u00a0mg vial supports many weeks of behavioural support at typical intranasal doses (24\u00a0IU \u2248 40\u00a0mcg per administration in human studies, with rodent doses scaled lower). <\/p>\n<h2>Comparaison \u2014 Ac\u00e9tate d'ocytocine vs Selank<\/h2>\n<p>L'ocytocine et <a href=\"https:\/\/medsbase.com\/fr\/selank\/\">Selank<\/a> are both small CNS-active peptides used in behavioural and mood-axis studies, but they target different receptors and behavioural domains. They are sometimes compared in studies because both are intranasally bioavailable and both produce measurable behavioural effects in published rodent and human studies despite being structurally and pharmacologically unrelated. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Ac\u00e9tate d'ocytocine<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Selank<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">9 acides amin\u00e9s (nonapeptide cyclique)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 acides amin\u00e9s (heptapeptide lin\u00e9aire)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Structure<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Macrocycle pont\u00e9 par un disulfure<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lin\u00e9aire avec un C-terminal amid\u00e9<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9cepteur principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">OXTR (coupl\u00e9 aux prot\u00e9ines G)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Non classique (modulation GABA, BDNF)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Signal comportemental<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lien social, confiance, comportement affiliatif<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Anxiolytique, r\u00e9silience au stress<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical dose (intranasal)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">24\u201340\u00a0UI (~40\u201365\u00a0mcg)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">300\u2013900\u00a0mcg<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 min (IV)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201330 min (voie intranasale)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Utilisation clinique approuv\u00e9e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9clenchement du travail, h\u00e9morragie postpartum<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Anxiolytique (Russie uniquement)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For behavioural-stacking, the two peptides have non-overlapping mechanisms (oxytocin acts on its own GPCR; Selank acts via GABA\/BDNF modulation), so co-administration is not pharmacologically redundant. Study protocols studying stress and social behaviour as joint endpoints sometimes use both arms. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> Conservez les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2\u20138 \u00b0C dans leur emballage d'origine pour le stockage \u00e0 court terme. Pour le stockage \u00e0 long terme non ouvert, congelez \u00e0 \u221220 \u00b0C. L'ac\u00e9tate d'ocytocine lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. La forme ac\u00e9tate est plus stable hygroscopiquement que la base libre, mais les flacons doivent tout de m\u00eame \u00eatre prot\u00e9g\u00e9s de l'humidit\u00e9 atmosph\u00e9rique. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 5.0\u00a0mL of bacteriostatic water yields a 1\u00a0mg\/mL working concentration; 0.04\u00a0mL delivers a 40\u00a0mcg dose (~24\u00a0IU). Swirl gently \u2014 do <strong>re\u00e7oit pas<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. For intranasal-vehicle formulations, the reconstituted solution can be transferred to a calibrated nasal-spray bottle delivering ~100\u00a0\u03bcL per pump. <strong>Apr\u00e8s reconstitution :<\/strong> Conservez au r\u00e9frig\u00e9rateur entre 2\u20138 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent l'int\u00e9grit\u00e9 du peptide et perturbent la liaison disulfure Cys1\u2013Cys6. Jetez tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Oxytocin Acetate used for in studies?<\/h3>\n<p>Oxytocin Acetate is used in studies investigating social behaviour and pair-bonding, autism spectrum and social cognition, trust and cooperation paradigms, stress and fear extinction, maternal and parental care, reproductive physiology, and wound healing. It is one of the most extensively studied neuropeptides in the published literature and serves as the canonical OXTR-axis compound. The pharmaceutical-grade oxytocin acetate sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved for non-clinical human use and is supplied strictly for clinical studies. <\/p>\n<h3>Quelle est la diff\u00e9rence entre l'ac\u00e9tate d'ocytocine et l'ocytocine base libre ?<\/h3>\n<p>The acetate counterion does not alter pharmacology \u2014 it dissociates rapidly in physiological solution. The acetate salt is used in pharmaceutical-grade peptide lyophilization because it improves long-term peptide stability, reduces hygroscopicity, and improves aqueous solubility relative to free-base oxytocin. All published behavioural and endocrine effects of oxytocin apply to the acetate salt at equivalent oxytocin content. <\/p>\n<h3>En quoi l'ocytocine diff\u00e8re-t-elle du Selank ?<\/h3>\n<p>Both are small CNS-active peptides used in behavioural support, but they target different receptors and behavioural domains. Oxytocin is a 9-amino-acid disulfide-bridged macrocyclic peptide that binds the OXTR G-protein-coupled receptor, with primary signal in social bonding and trust paradigms. Selank is a 7-amino-acid linear heptapeptide that acts via GABA modulation and BDNF expression, with primary signal in anxiolysis and stress resilience. The two are pharmacologically unrelated. <\/p>\n<h3>What is the typical Oxytocin dose?<\/h3>\n<p>Published human intranasal protocols typically use 24\u201340\u00a0IU per administration (1\u00a0IU \u2248 1.7\u00a0mcg, so 24\u00a0IU \u2248 40\u00a0mcg). Rodent doses are scaled lower in absolute mass but higher in mg\/kg. A 5\u00a0mg vial reconstituted with 5.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 40\u00a0mcg per 0.04\u00a0mL. <\/p>\n<h3>L'Oxytocine Ac\u00e9tate est-elle approuv\u00e9e par la FDA ?<\/h3>\n<p>Pharmaceutical injectable oxytocin (Pitocin, Syntocinon) is FDA-approved for specific obstetric indications \u2014 labour induction, postpartum haemorrhage control, and milk-letdown facilitation \u2014 manufactured to GMP standards by approved pharmaceutical manufacturers. <\/p>\n<h3>Comment conserver l'Oxytocine Ac\u00e9tate ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stockage \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide et peuvent perturber le pont disulfure. Prot\u00e9ger de la lumi\u00e8re directe \u00e0 tout moment. <\/p>\n<h3>Comment reconstituer l'Oxytocine Ac\u00e9tate ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> Agitez doucement le flacon \u2014 une agitation vigoureuse peut perturber la liaison disulfure. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 5,0 mL de diluant, la concentration de travail est de 1 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Oxytocin Acetate in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Oxytocin be administered intranasally in studies?<\/h3>\n<p>Yes \u2014 intranasal administration is one of the most-cited studies delivery routes for oxytocin behavioural studies. Intranasal oxytocin produces measurable CNS effects on social behaviour, trust, and stress reactivity without raising peripheral plasma oxytocin to physiologically meaningful levels. The exact mechanism of CNS access remains an active studies question (olfactory and trigeminal nerve transport, cribriform plate diffusion, or peripheral feedback). Subcutaneous and intracerebroventricular routes are also documented in rodent studies. <\/p>\n<h3>Quelle est la demi-vie de l'ocytocine ?<\/h3>\n<p>In published studies, oxytocin has a plasma half-life of approximately 3\u20135 minutes following intravenous administration. The short peripheral half-life is due to rapid metabolism by oxytocinase (also called cystinyl aminopeptidase) and other peptidases. Behavioural effects following intranasal administration outlast plasma clearance because central oxytocin compartments are distinct from peripheral circulation. <\/p>\n<h3>Pourquoi le pont disulfure est-il important ?<\/h3>\n<p>La liaison disulfure Cys1\u2013Cys6 verrouille l'ocytocine dans la conformation cyclique n\u00e9cessaire \u00e0 la liaison au r\u00e9cepteur. La r\u00e9duction du pont disulfure convertit l'ocytocine en une forme lin\u00e9aire inactive \u2014 c'est pourquoi les proc\u00e9dures de reconstitution \u00e9vitent sp\u00e9cifiquement les secousses vigoureuses et les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation, qui peuvent perturber le pont et d\u00e9grader l'activit\u00e9 peptidique. Le neuropeptide \u00e9troitement apparent\u00e9, la vasopressine, a la m\u00eame architecture de pont disulfure avec une seule diff\u00e9rence d'acide amin\u00e9 en position 3 (Ph\u00e9 dans la vasopressine vs Ile dans l'ocytocine). <\/p>\n<h3>Does Oxytocin cause side reported effects?<\/h3>\n<p>The most consistent finding in oxytocin is dose-dependence of behavioural effects \u2014 the response is not monotonic at high doses, and very large doses can produce paradoxical effects. Acute peripheral effects can include uterine contraction (relevant in pregnancy study models) and modest vasoactive effects at supraphysiological doses. Long-term behavioural support has reported context-dependent effects \u2014 e.g., increased in-group affiliation can be accompanied by increased out-group bias in some social-cognition paradigms. <\/p>\n<h3>How long does Oxytocin take to show effects in preclinical studies?<\/h3>\n<p>Acute behavioural effects on social-recognition, partner-preference, and trust-game paradigms are detectable within 30\u201360 minutes of intranasal administration in human and rodent studies. Peripheral effects (uterine contraction, milk-ejection) occur within seconds of intravenous administration due to direct OXTR coupling to PLC\/IP<sub>3<\/sub>Puis-je commander de l'ac\u00e9tate d'ocytocine pour une livraison internationale ?<sup>2+<\/sup> Oui. MedsBase exp\u00e9die l'ac\u00e9tate d'ocytocine dans le monde entier via notre r\u00e9seau d\u00e9di\u00e9 d'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre. <\/p>\n<h3>Autres peptides pour la recherche sur le SNC, le comportement et l'affect<\/h3>\n<p>Oui. MedsBase exp\u00e9die l'ac\u00e9tate d'oxytocine dans le monde entier depuis notre r\u00e9seau d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for CNS, Behavioural, and Affective Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide tuftsin analog \u2014 GABA\/BDNF stress resilience<\/li>\n<li><a href=\"\/fr\/semax\/\"><strong>Semax<\/strong><\/a> \u2014 Nootropique heptapeptidique d\u00e9velopp\u00e9 en Russie \u2014 modulation m\u00e9lanocortine et dopaminergique<\/li>\n<li><a href=\"\/fr\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin receptor agonist \u2014 CNS-active small peptide for sexual-behaviour studies<\/li>\n<li><a href=\"\/fr\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 longevity and circadian rhythm support<\/li>\n<li><a href=\"\/fr\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tissue-recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore CNS-active peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s incluant <a href=\"https:\/\/medsbase.com\/fr\/selank\/\">Selank<\/a> for anxiolytic GABA-axis studies, <a href=\"https:\/\/medsbase.com\/fr\/semax\/\">Semax<\/a> for nootropic melanocortin-axis studies, and <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141<\/a> for melanocortin sexual-behaviour studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Neuropeptide cyclique \u00e0 9 acides amin\u00e9s<br \/>\n\u2705 Agoniste du r\u00e9cepteur OXTR<br \/>\n\u2705 Social-bonding &amp; affiliative behavioural support<br \/>\n\u2705 Peptide biodisponible par voie intranasale<br \/>\n\u2705 Forme de sel d'ac\u00e9tate \u2014 stabilit\u00e9 am\u00e9lior\u00e9e<\/p>\n<p><strong>Ac\u00e9tate d'ocytocine<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70970,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6274,5441],"class_list":["post-70705","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-oxytocin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70705"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70970"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70705"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70705"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70705"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}